AstraZeneca blood disorder drug recommended for EU nod Ruchika Sharma27 Feb 2024 11:29 AM ISTCambridge: AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) as an...
AstraZeneca Gets CDSCO Panel nod to study Anti-cancer Drug Datopotamab Deruxtecan and Durvalumab Dr. Divya Colin23 Feb 2024 6:00 PM ISTNew Delhi: The drug major AstraZeneca has got approval from the Subject Expert Committee SEC functional under the Central Drug Standard Control...
AstraZeneca completes acquisition of Gracell Biotechnologies Ruchika Sharma23 Feb 2024 12:30 PM ISTGracell will operate as a wholly owned subsidiary of AstraZeneca, with operations in China and the US.
AstraZeneca concludes acquisition of Icosavax Ruchika Sharma20 Feb 2024 12:30 PM ISTCambridge: AstraZeneca has announced the successful completion of the acquisition of Icosavax, Inc., a US-based clinical-stage biopharmaceutical...
AstraZeneca-Daiichi Sankyo application for Datopotamab deruxtecan accepted in US for patients with previously treated advanced nonsquamous non-small cell lung cancer Ruchika Sharma19 Feb 2024 4:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US...
CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal to Study Capivasertib Plus Abiraterone Dr. Divya Colin18 Feb 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
AstraZeneca Tagrisso with chemotherapy approved in US for EGFR-mutated advanced lung cancer Ruchika Sharma17 Feb 2024 12:00 PM ISTTagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against CNS metastases.
AstraZeneca, BioInvent ink pact to evaluate BI-1206 in combo with rituximab, Calquence Ruchika Sharma12 Feb 2024 4:30 PM ISTSweden: BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...
AstraZeneca-Ionis Eplontersen granted USFDA fast track designation for transthyretin-mediated amyloid cardiomyopathy Ruchika Sharma10 Feb 2024 3:30 PM ISTCarlsbad: Ionis Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis...
AstraZeneca Enhertu granted priority review in US for metastatic HER2-positive solid tumours Ruchika Sharma31 Jan 2024 12:45 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been...
AstraZeneca Voydeya approved in Japan for paroxysmal nocturnal haemoglobinuria Ruchika Sharma21 Jan 2024 12:30 PM ISTCambridge: AstraZeneca has announced that Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal...
Justify Durvalumab dose: CDSCO Panel Tells AstraZeneca on Study of Dato-DXd and Durvalumab Dr. Divya Colin8 Jan 2024 6:00 PM ISTNew Delhi: Reviewing the drug major AstraZeneca's Phase III clinical trial protocol of the anti-cancer drug of Dato-DXd and Durvualumab, the Subject...
